- Home
- AIIR vs JANX Comparison
AIIR vs JANX Comparison
Compare AIIR & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIIR | JANX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 975.7M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AIIR | JANX |
|---|---|---|
| Price | $7.74 | $17.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 8.8K | ★ 670.6K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.29 | $12.12 |
| 52 Week High | $8.64 | $35.34 |
Technical Indicators
Market Signals| Indicator | AIIR | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 58.06 | 63.92 |
| Support Level | $6.50 | $13.13 |
| Resistance Level | $8.40 | $30.47 |
| Average True Range (ATR) | 0.67 | 0.58 |
| MACD | 0.10 | 0.12 |
| Stochastic Oscillator | 56.84 | 83.58 |
Price Performance
Historical ComparisonAbout AIIR Air Global PLC Ordinary Shares
AIR Global PLC operates in the social inhalation products sector and has operations across multiple international markets. Its portfolio includes businesses and products related to shisha and hookah, including flavored shisha molasses, hookah and shisha e-commerce platforms, and charcoal-free shisha devices. The company also conducts product research and testing in partnership with independent laboratories to support the development of inhalation-related products and technologies.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.